HRs for cancer among women who used antidiabetic medications (using time-dependent variables), stratified by HbA1c
| Overall | HbA1c <7.0% (<53 mmol/mol) | HbA1c 7.0–9.4% (53–80 mmol/mol) | HbA1c ≥9.5% (≥80 mmol/mol) | |||||
|---|---|---|---|---|---|---|---|---|
| Adjusted HR* | 95% CI | Adjusted HR* | 95% CI | Adjusted HR* | 95% CI | Adjusted HR* | 95% CI | |
| Breast cancer | ||||||||
| Combination† vs metformin only | 0.85 | 0.69 to 1.04 | 0.96 | 0.51 to 1.82 | 0.83 | 0.62 to 1.11 | 1.06 | 0.73 to 1.55 |
| Non-metformin drugs vs metformin only | 0.89 | 0.74 to 1.09 | 0.87 | 0.55 to 1.37 | 0.98 | 0.75 to 1.30 | 0.84 | 0.57 to 1.25 |
| All cancers combined | ||||||||
| Combination† vs metformin only | 0.92 | 0.77 to 1.10 | 1.07 | 0.61 to 1.88 | 0.85 | 0.66 to 1.10 | 1.15 | 0.83 to 1.60 |
| Non-metformin drugs vs metformin only | 0.93 | 0.79 to 1.11 | 0.98 | 0.65 to 1.48 | 1.00 | 0.78 to 1.28 | 0.85 | 0.60 to 1.20 |
*Adjusted for: age of index diabetes diagnosis, race/ethnicity, ERT status, statin use, Charlson comorbidity index, and outpatient utilization.
†Combination includes metformin use.
ERT, estrogen replacement therapy; HbA1c, glycated hemoglobin.